8-K: Chelsea Clinton Departs Clover Health Board

Chelsea Clinton, the longest-serving member of Clover Health's Board of Directors, has concluded her service effective October 31, 2025, after over eight years.

Summary

• Chelsea Clinton notified Clover Health Investments, Corp. of her intention to conclude her service on the Board of Directors and its Talent and Compensation Committee and Nominating and Corporate Governance Committee, effective October 31, 2025.
• Ms. Clinton's decision to step down is not due to any disagreement with the company regarding its operations, policies, or practices.
• She served on the Board for over eight years, joining in early 2017, and played a role in guiding Clover's evolution from a private company with 30,000 members to a publicly traded organization serving over 100,000 seniors.
• The Board intends to fill the vacancy created by her departure as soon as practicable.
• The authorized number of directors under the company's Bylaws will remain unchanged at nine, and the Board will continue to operate with two vacant seats following Ms. Clinton's departure.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While a director's departure can be seen as a negative, the filing explicitly states it was not due to disagreement and highlights her significant, positive contributions over eight years. The company's commitment to filling the vacancy and maintaining a strong board also contributes to a stable outlook.

Positives

• Ms. Clinton's departure is not a result of any disagreement with the company, indicating an amicable separation.
• Her over eight years of dedicated service provided significant guidance during the company's growth from a private entity to a public one, expanding its member base from 30,000 to over 100,000 seniors.
• Management expressed gratitude for her contributions, highlighting her perspective, insight, and commitment to the company's mission.

Negatives

• The Board will operate with two vacant seats following Ms. Clinton's departure, potentially impacting governance capacity until new directors are appointed.
• The company loses an experienced director who served on key committees (Talent & Compensation and Nominating and Corporate Governance).

Risks

• The Board will continue to operate with two vacant seats, which could potentially strain the remaining directors or delay certain governance functions until the vacancies are filled.

Future Outlook

The Board intends to fill the vacancy created by Ms. Clinton's departure as soon as practicable. The company remains committed to maintaining a strong, diverse, and experienced Board to guide its ongoing growth and mission.

Management Comments

• Vivek Garipalli, Executive Chairperson and founder of Clover Health, stated: "Chelsea has been an invaluable voice on our Board since Clovers earliest days. Her perspective, insight, and steadfast commitment to our mission have helped shape Clover into the company it is today."
• Chelsea Clinton commented: "It has been a privilege to help guide Clover as it has evolved from a private company with a bold idea to use technology to improve healthcare, into a public company thats delivering on that promise for more than 100,000 members."
• Andrew Toy, CEO of Clover Health, noted: "Her commitment to our mission and belief in the power of technology to improve care have shaped how we think and operate as a company. As we move forward, were grateful for her leadership and excited to continue advancing the work she helped set in motion."

Industry Context

Clover Health operates in the physician enablement technology and Medicare Advantage sectors, focusing on improving healthcare access and outcomes for seniors through its software platform, Clover Assistant. The departure of a long-serving director, even if amicable, is a common occurrence in the dynamic healthcare technology industry, where boards evolve with company growth and strategic shifts.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to assess against global benchmarks.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: The composition of the Board of Directors is a key aspect of corporate governance and can influence investor confidence. The amicable nature of the departure and the stated intention to fill vacancies may mitigate negative impact.
• Employees: Changes in board leadership can affect strategic direction and company culture, though the filing suggests continuity of mission.

Next Steps

• The Board intends to fill the vacancy created by Ms. Clinton's departure as soon as practicable.

Key Dates

Keywords

Clover Health, CLOV, Chelsea Clinton, Board of Directors, Director Resignation, Corporate Governance, SEC Filing, 8-K, Healthcare Technology, Medicare Advantage